1
|
Ellis AA, Geary SM, Salem AK. Heterologous prime-boost vaccine using antigen-loaded microparticles and adenovirus (encoding antigen) enhances cellular immune responses and antitumor activity. Int J Pharm 2023; 638:122932. [PMID: 37031810 DOI: 10.1016/j.ijpharm.2023.122932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2022] [Revised: 03/25/2023] [Accepted: 04/02/2023] [Indexed: 04/11/2023]
Abstract
Heterologous prime-boost vaccines have the potential to promote higher immune responses than homologous prime-boost vaccines and were used in this murine study to investigate the effect on the magnitude of the cellular (and humoral) antigen-specific immune responses and antitumor efficacy when a microparticle formulation (prime) is combined with an adenoviral vaccine (boost). Specifically, the prime comprised chick egg ovalbumin (OVA; 25 µg/dose), used here as a model tumor antigen (TA), encapsulated in microparticles (∼700 nm diameter) made from the biodegradable polymer, 50:50 poly(lactic-co-glycolic acid) (PLGA); while attenuated adenovirus (type 5) encoding OVA (Ad5OVA; 108 PFU/dose) was employed as the boost. The ability of OVA-loaded microparticles to enhance OVA-specific antibody responses, OVA-specific CD3 + CD8 + T cell responses and antitumor activity (i.e., protection against OVA-expressing tumor-challenge) to the heterologous prime-boost vaccine was investigated; and it was found that this prime-boost combination could significantly enhance OVA-specific cellular responses compared to all other vaccination groups and was the only group to confer a significant survival advantage over the unvaccinated group (naïve) in a prophylactic animal tumor model. This finding illustrates the potential for combining TA-loaded PLGA-based microparticles with other vaccine formats to improve tumor-specific cellular immune responses.
Collapse
Affiliation(s)
- Alexis A Ellis
- 180 S Grand Avenue, Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA
| | - Sean M Geary
- 180 S Grand Avenue, Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA.
| | - Aliasger K Salem
- 180 S Grand Avenue, Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA.
| |
Collapse
|
2
|
Farhang-Sardroodi S, Korosec CS, Gholami S, Craig M, Moyles IR, Ghaemi MS, Ooi HK, Heffernan JM. Analysis of Host Immunological Response of Adenovirus-Based COVID-19 Vaccines. Vaccines (Basel) 2021; 9:861. [PMID: 34451985 PMCID: PMC8402548 DOI: 10.3390/vaccines9080861] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2021] [Revised: 07/22/2021] [Accepted: 07/27/2021] [Indexed: 12/18/2022] Open
Abstract
During the SARS-CoV-2 global pandemic, several vaccines, including mRNA and adenovirus vector approaches, have received emergency or full approval. However, supply chain logistics have hampered global vaccine delivery, which is impacting mass vaccination strategies. Recent studies have identified different strategies for vaccine dose administration so that supply constraints issues are diminished. These include increasing the time between consecutive doses in a two-dose vaccine regimen and reducing the dosage of the second dose. We consider both of these strategies in a mathematical modeling study of a non-replicating viral vector adenovirus vaccine in this work. We investigate the impact of different prime-boost strategies by quantifying their effects on immunological outcomes based on simple system of ordinary differential equations. The boost dose is administered either at a standard dose (SD) of 1000 or at a low dose (LD) of 500 or 250 vaccine particles. Results show dose-dependent immune response activity. Our model predictions show that by stretching the prime-boost interval to 18 or 20, in an SD/SD or SD/LD regimen, the minimum promoted antibody (Nab) response will be comparable with the neutralizing antibody level measured in COVID-19 recovered patients. Results also show that the minimum stimulated antibody in SD/SD regimen is identical with the high level observed in clinical trial data. We conclude that an SD/LD regimen may provide protective capacity, which will allow for conservation of vaccine doses.
Collapse
Affiliation(s)
- Suzan Farhang-Sardroodi
- Modelling Infection and Immunity Lab, Mathematics Statistics, York University, Toronto, ON M3J 1P3, Canada; (C.S.K.); (S.G.)
- Centre for Disease Modelling (CDM), Mathematics Statistics, York University, Toronto, ON M3J 1P3, Canada;
| | - Chapin S. Korosec
- Modelling Infection and Immunity Lab, Mathematics Statistics, York University, Toronto, ON M3J 1P3, Canada; (C.S.K.); (S.G.)
- Centre for Disease Modelling (CDM), Mathematics Statistics, York University, Toronto, ON M3J 1P3, Canada;
| | - Samaneh Gholami
- Modelling Infection and Immunity Lab, Mathematics Statistics, York University, Toronto, ON M3J 1P3, Canada; (C.S.K.); (S.G.)
- Centre for Disease Modelling (CDM), Mathematics Statistics, York University, Toronto, ON M3J 1P3, Canada;
| | - Morgan Craig
- Sainte-Justine University Hospital Research Centre and Department of Mathematics and Statistics, Université de Montréal, Montreal, QC H3T 1J4, Canada;
| | - Iain R. Moyles
- Centre for Disease Modelling (CDM), Mathematics Statistics, York University, Toronto, ON M3J 1P3, Canada;
| | - Mohammad Sajjad Ghaemi
- Digital Technologies Research Centre, National Research Council Canada, Toronto, ON C1A 4P3, Canada; (M.S.G.); (H.K.O.)
| | - Hsu Kiang Ooi
- Digital Technologies Research Centre, National Research Council Canada, Toronto, ON C1A 4P3, Canada; (M.S.G.); (H.K.O.)
| | - Jane M. Heffernan
- Modelling Infection and Immunity Lab, Mathematics Statistics, York University, Toronto, ON M3J 1P3, Canada; (C.S.K.); (S.G.)
- Centre for Disease Modelling (CDM), Mathematics Statistics, York University, Toronto, ON M3J 1P3, Canada;
| |
Collapse
|